Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I¹²⁵ implant brachytherapy for prostate cancer. A longitudinal study of a single-institution

References

• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–81
   PubMed Web of Science ®Google Scholar
• Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315–21
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124–37
   PubMed Web of Science ®Google Scholar
• Hayashi N, Izumi K, Sano F, et al. Ten-year outcomes of I low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan. World J Urol 2015. [Epub ahead of print]. doi: 10.1007/s00345-015-1480-0
   PubMed Web of Science ®Google Scholar
• Li X, Fang D, Cooperberg MR, et al. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol 2014;32:1061–6
   PubMed Web of Science ®Google Scholar
• Huyghe E, Delaunay B, Njomnang Soh P, et al. Proposal for a predictive model of erectile function after permanent (125)I prostate brachytherapy for localized prostate cancer. Int J Impot Res 2013;25:121–6
   PubMed Web of Science ®Google Scholar
• Ong WL, Hindson BR, Beaufort C, et al. Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer. Radiother Oncol 2014;112:72–6
   PubMed Web of Science ®Google Scholar
• Herbert C, Morris WJ, Keyes M, et al. Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort study. Radiother Oncol 2012;103:228–32
   PubMed Web of Science ®Google Scholar
• Reis LO, Sanches BC, Zani EL, et al. PSA-nadir at 1 year as a sound contemporary prognostic factor for low-dose-rate iodine-125 seeds brachytherapy. World J Urol 2014;32:753–9
   PubMed Web of Science ®Google Scholar
• Guarneri A, Botticella A, Ragona R, et al. Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. World J Urol 2013;31:411–15
   PubMed Web of Science ®Google Scholar
• Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002;14:245–50
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83
   PubMedGoogle Scholar
• Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012;11:6–19
   PubMed Web of Science ®Google Scholar
• Roach M, III Hanks G, Thames H, Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu T, Rossi PJ, et al. Influence of vascular comorbidities and race on erectile dysfunction after prostate cancer radiotherapy. J Sex Med 2013;10:2108–14
   PubMed Web of Science ®Google Scholar
• Sullivan JF, Stember DS, Deveci S, et al. Ejaculation profiles of men following radiation therapy for prostate cancer. J Sex Med 2013;10:1410–16
   PubMed Web of Science ®Google Scholar
• Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med 2013;10:102–11
   PubMed Web of Science ®Google Scholar
• Incrocci L, Jensen PT. Pelvic radiotherapy and sexual function in men and women. J Sex Med 2013;10:53–64
   PubMed Web of Science ®Google Scholar
• Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306:1205–14
   PubMed Web of Science ®Google Scholar
• Corona G, Lee DM, Forti G, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med 2010;7:1362–80
   PubMed Web of Science ®Google Scholar
• Favilla V, Cimino S, Salamone C, et al. Risk factors of sexual dysfunction after transurethral resection of the prostate (TURP): a 12 months follow-up. J Endocrinol Invest 2013;36:1094–8
   PubMed Web of Science ®Google Scholar
• Russo GI, Cimino S, Fragala E, et al. Insulin resistance is an independent predictor of severe lower urinary tract symptoms and of erectile dysfunction: results from a cross-sectional study. J Sex Med 2014;11:2074–82
   PubMed Web of Science ®Google Scholar
• Merrick GS, Butler WM, Galbreath RW, et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;52:893–902
   PubMed Web of Science ®Google Scholar
• Merrick GS, Butler WM, Wallner KE, et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;62:437–47
   PubMed Web of Science ®Google Scholar
• Solan AN, Cesaretti JA, Stone NN, Stock RG. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009;73:1468–74
   PubMed Web of Science ®Google Scholar
• Munro NP, Al-Qaisieh B, Bownes P, et al. Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years. Radiother Oncol 2010;96:34–7
   PubMed Web of Science ®Google Scholar